Myo-inositol Sleep Quality Randomized Trial: What the Evidence Says

Quick Answer

Myo-inositol Sleep Quality Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• The global prevalence of PCOS increased from 36.7 to 69.5 million between 1990 and 2021. [Subakathulla Sumayyah (2026); evidence level 3]
• Emerging evidence underscores that OS is not a mere byproduct of metabolic imbalance but a central driver that disrupts insulin signaling, amplifies androgen biosynthesis, and impairs folliculogenesis. [Subakathulla Sumayyah (2026); evidence level 3]
• Besides diabetes, metformin has found off-label applications, most notably in PCOS and weight management, but also in other areas as cardiovascular diseases, oncology, and neurological disorders. [Russo Michele (2025); evidence level 4]
• Metformin appears to have a synergistic relationship with a healthy gut microbiota environment, as coadministration of metformin with probiotics improved metabolic function in patients with T2DM. [Russo Michele (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For myo-inositol sleep quality randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Subakathulla Sumayyah (2026). Redox-endocrine triad in PCOS: can vitamin D, myo-inositol, and melatonin synergize as bioactive cocktails?. DOI: 10.3389/fendo.2026.1825853. PMCID: PMC13160802. PMID: 42130739. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13160802/
• Russo Michele (2025). Metformin and Myo-Inositol: A Comparative Analysis. DOI: 10.1159/000549646. PMCID: PMC12721718. PMID: 41269915. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12721718/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.